Archived Webcasts
AmeirsourceBergen Specialty Group has archived selected presentations to provide instant access to industry information, forecasts and guidance. Click on the topic below to access previous webcasts. Or to view our list of current, live webcasts, click here
Wheels of Change in Washington: How Presidential Candidates, Congress and CMS May Impact Patient Support Services
Originally broadcast: June 26, 2008
Along with the war in Iraq and the economy, healthcare has become a crucial, hot-button issue for the presidential candidates. Though their approaches to healthcare reform differ dramatically in many areas, the candidates share a common promise—change. Depending on which candidate emerges victorious, what does this change actually mean for pharmaceutical manufacturers and for the healthcare industry as a whole? And how do legislative and Medicare changes continue to influence patient care?
Discover how the presidential candidates, Congress and CMS may impact patient support services through the remainder of the year and beyond. View our on-demand webcast “Wheels of Change in Washington."
Is Patient Compliance Your Next Blockbuster Drug?
Originally broadcast: May 28, 2008
Pharmaceutical manufacturers spend billions of dollars each year on the research and development that will produce their next successful product. But in the wake of stagnant development pipelines and growing competition from generics, many manufacturers are taking a closer look at patient compliance as a way to drive product success and boost financial results. Join us for an in-depth Webcast that provides insight on how compliance rates affect clinical outcomes, market perception and product revenue—as well as what manufacturers can do about it.
Jan Nielsen of ICS and Mike Eaddy of Xcenda (both companies of AmerisourceBergen Specialty Group) will present analysis and case examples that will allow attendees to learn more about:
- Market conditions that make patient compliance more important than ever
- The impact that non-compliance can have on patient results and how that affects the real-world image and effectiveness of products
- How and why patients remain compliant with prescribed therapy
- How pharmaceutical companies can accurately measure patient compliance to understand the size of their opportunities
- Case examples of how selected manufacturers have increased compliance and enhanced product success
Featured Speakers
Jan Nielsen, RN, MPA
Vice President, Clinical Services
ICS
Mike Eaddy, PharmD, PhD
Senior Director
Comparative Effectiveness: Emerging use with public and private payers and potential impact on manufacturers
Originally broadcast: May 20, 2008
Rising costs pose a significant challenge to the U.S. healthcare system. Congress, public and private payers and other stakeholders have growing interest in using comparative effectiveness research to control costs and support value-based purchasing. Policymakers continue to examine the framework for this research at the national level. Additionally, private payers have already begun comparing the effectiveness of products. Widespread use of comparative effectiveness data could have profound implications for manufacturers as well as the entire healthcare system.
Learning Objectives:
- Understand the definition and scope of comparative effectiveness
- Gain insight into current comparative effectiveness research efforts
- See analysis of recent legislative and policy developments
- Discover potential implications of comparative effectiveness research on manufacturers and other stakeholders
- Identify strategies and considerations for navigating the comparative effectiveness landscape
- Learn methods for implementing comparative effectiveness research
Moderator:
Peyton Howell, M.H.A., President, Pharma & Specialty Services, AmerisourceBergen Specialty Group
Presenters:
Grant Bagley, M.D., J.D., Partner, HillCo Partners
Thomas Bramley, R.Ph., Ph.D., Senior Director, Xcenda
Gene Reeder, R.Ph., Ph.D., Director, Xcenda
Market Value Plan (MVP): A comprehensive approach to developing a product value proposition and reimbursement strategy
Originally broadcast: April 29, 2008
Several external factors have impacted the way pharmaceutical manufacturers commercialize their products and compete in the marketplace. Increasing payer influence, pressure from generic entries and greater focus on comparative product effectiveness all demand that products have sound value propositions. Additionally, the switch from development of traditional, small molecule products to specialty products has expanded the set of reimbursement challenges. These market dynamics have forced brand managers to change their approach to brand planning and product strategy. This case-based webcast presents a comprehensive approach to addressing these issues and developing a sound product value proposition.
Presenters:
Sigrid Schreiner, MHA, CMPE, Vice President, Xcenda (View Bio)
Matt Sarnes, PharmD, Executive Director, Xcenda (View Bio)
Medicare Part D's Impact on Patient Assistance Programs
Originally broadcast: June 14, 2007
View a free, informative Webcast featuring the latest on this complex federal program
Pharmaceutical companies rely on patient assistance programs as an essential strategy for maintaining accessibility to vital drugs. But now, in the world of Medicare Part D, these same assistance programs can present unprecedented complexities. Join us for an in-depth Webcast that explores Medicare Part D’s influence on patients, the concerns and requirements of federal agencies and solutions for manufacturers.
Presenter: Tracy Foster, MBA, President, Lash Group
